Ligand Pharmaceuticals Financials
LGND Stock | USD 121.47 1.08 0.88% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.11 | 0.12 |
|
| |||||
Current Ratio | 14.86 | 14.1478 |
|
|
The financial analysis of Ligand Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Ligand Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Ligand | Select Account or Indicator |
Understanding current and past Ligand Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ligand Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Ligand Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Ligand Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ligand Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ligand Pharmaceuticals' management manipulating its earnings.
Ligand Pharmaceuticals Stock Summary
Ligand Pharmaceuticals competes with Passage Bio, Oric Pharmaceuticals, Lyell Immunopharma, Design Therapeutics, and Ascendis Pharma. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company was incorporated in 1987 and is based in San Diego, California. Ligand Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 154 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US53220K5048 |
CUSIP | 53220K504 53220K207 53220K215 53220K173 53220K181 53220K199 |
Location | California; U.S.A |
Business Address | 555 Heritage Drive, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ligand.com |
Phone | 858 550 7500 |
Currency | USD - US Dollar |
Ligand Pharmaceuticals Key Financial Ratios
Return On Equity | 0.06 | ||||
Profit Margin | 0.30 % | ||||
Operating Margin | 0.21 % | ||||
Price To Sales | 15.19 X | ||||
Revenue | 131.31 M |
Ligand Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.5B | 1.4B | 1.3B | 762.7M | 787.2M | 451.3M | |
Other Current Liab | 11.2M | 58.4M | 31.8M | 15.7M | 12.7M | 19.8M | |
Net Debt | (362.6M) | 406.9M | 316.7M | 87.7M | (16.8M) | (15.9M) | |
Retained Earnings | 400.1M | 392.0M | 449.1M | 450.9K | 503.0M | 528.2M | |
Accounts Payable | 2.4M | 3.8M | 8.4M | 5.3M | 2.4M | 2.3M | |
Cash | 1.0B | 47.6M | 19.5M | 45.0K | 23.0M | 21.8M | |
Net Receivables | 41.7M | 59.1M | 91.6M | 35.0M | 39.3M | 22.8M | |
Other Current Assets | 4.7M | 3.8M | 4.7M | 3.4M | 3.8M | 3.6M | |
Total Liab | 702.1M | 652.8M | 479.8M | 165.2M | 86.3M | 82.0M | |
Total Current Assets | 1.1B | 500.6M | 464.8M | 263.6M | 237.4M | 218.7M | |
Short Term Debt | 1.2M | 8.5M | 1.4M | 77.4M | 410K | 389.5K | |
Inventory | 7.3M | 26.5M | 27.3M | 13.3M | 24.0M | 25.2M | |
Other Liab | 61.8M | 104.7M | 101.9M | 56.0M | 64.4M | 43.3M | |
Other Assets | 28.0M | 62.3M | 58.8M | 13.3M | 15.3M | 14.5M | |
Long Term Debt | 609.9M | 639.0M | 442.3M | 320.7M | 368.8M | 387.3M | |
Intangible Assets | 20.1M | 11.0M | 10.1M | 10.2M | 366.9M | 385.2M | |
Good Will | 305.7M | 785.0M | 735.0M | 448.1M | 103.4M | 98.2M |
Ligand Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 35.7M | 27.4M | 18.7M | 1.8M | 656K | 623.2K | |
Total Revenue | 120.3M | 186.4M | 277.1M | 196.2M | 131.3M | 101.8M | |
Gross Profit | 108.9M | 156M | 215.0M | 143.4M | 96.3M | 86.4M | |
Operating Income | (5.7M) | 8.6M | 78.9M | (25.5M) | 11.9M | 12.5M | |
Ebit | (5.7M) | 41.1M | 91.8M | 11.0M | 64.3M | 67.5M | |
Ebitda | (804.5M) | 69.1M | 133.2M | 54.4M | 101.7M | 106.8M | |
Cost Of Revenue | 11.3M | 30.4M | 62.2M | 52.8M | 35.0M | 19.3M | |
Income Before Tax | 796.6M | (10.5M) | 47.3M | 36.0M | 63.7M | 66.8M | |
Net Income | 629.3M | (3.0M) | 57.1M | (5.2M) | 52.2M | 54.8M | |
Income Tax Expense | 167.3M | (7.6M) | (10.3M) | 41.2M | 9.8M | 6.5M | |
Research Development | 55.9M | 59.4M | 69.0M | 36.1M | 24.5M | 33.6M | |
Tax Provision | 167.3M | (7.6M) | (10.3M) | 41.2M | 49.6M | 52.1M | |
Interest Income | 28.4M | 8.1M | 886K | 2.0M | 7.0M | 11.2M | |
Net Interest Income | (7.3M) | (19.3M) | (18.7M) | 247K | 6.3M | 6.6M |
Ligand Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (47.5M) | (24.3M) | (28.4M) | 25.5M | (22.1M) | (20.9M) | |
Free Cash Flow | (31.9M) | 50.1M | 70.0M | 119.9M | (4.3M) | (4.5M) | |
Depreciation | 43.7M | 28.0M | 50.9M | 51.4M | 35.6M | 37.4M | |
Other Non Cash Items | (797.5M) | 28.0M | (7.3M) | (26.8M) | (41.3M) | (43.3M) | |
Capital Expenditures | 2.6M | 4.5M | 8.8M | 17.9M | 3.5M | 6.6M | |
Net Income | 629.3M | (3.0M) | 57.1M | (33.4M) | 52.2M | 54.8M | |
End Period Cash Flow | 72.3M | 48.0M | 19.5M | 45.0M | 23.0M | 21.8M | |
Change To Inventory | (2.1M) | (17.8M) | (427K) | 12.1M | (10.9M) | (10.3M) | |
Investments | (326.8M) | 615.7M | 40.0M | 163.6M | (8.7M) | (9.1M) | |
Change Receivables | (29.5M) | 25.5M | (26.1M) | (28.6M) | (25.8M) | (24.5M) | |
Net Borrowings | (27.3M) | (222.2M) | (164.9M) | (261.0M) | (234.9M) | (223.2M) | |
Change To Netincome | (717.9M) | (1.8M) | 6.2M | 47.9M | 43.1M | 45.3M |
Ligand Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ligand Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Ligand Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ligand Pharmaceuticals competition to find correlations between indicators driving Ligand Pharmaceuticals's intrinsic value. More Info.Ligand Pharmaceuticals Incorporated is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.22 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ligand Pharmaceuticals Incorporated is roughly 4.62 . At present, Ligand Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ligand Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Ligand Pharmaceuticals Systematic Risk
Ligand Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ligand Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Ligand Pharmaceuticals correlated with the market. If Beta is less than 0 Ligand Pharmaceuticals generally moves in the opposite direction as compared to the market. If Ligand Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ligand Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ligand Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Ligand Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Ligand Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ligand Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ligand Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Ligand Pharmaceuticals November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ligand Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ligand Pharmaceuticals Incorporated. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ligand Pharmaceuticals Incorporated based on widely used predictive technical indicators. In general, we focus on analyzing Ligand Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ligand Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 2.67 | |||
Information Ratio | 0.0359 | |||
Maximum Drawdown | 17.78 | |||
Value At Risk | (4.58) | |||
Potential Upside | 4.11 |
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |